




GAIA
NK-like cell
platform
A breakthrough in
eliminating solid tumors
A major limitation of adoptive cell immunotherapy is its insufficient therapeutic efficacy, even with the use of genetically modified chimeric antigen receptor (CAR)-T and natural killer (NK) cells.
Our platform enables the production of NK-like cells that effectively eliminate solid tumors, without any genetic modification.


GAIA's antibody-anchoring
and activating peptide
A peptide-based platform
to generate GAIA NK-like cells
targeting a variety of tumors
GAAAP enables the generation of GAIA NK-like cells that maintain their active state in vivo and specifically target cancer cell-expressed proteins.
Core Technology IINews
-
News
AMED Released to Support a Clinical Trial of GAIA-102 to Treat Pediatric Solid Tumors
More -
News
Innate Killer Summit 2022 at San Diego, March 30- April 1:
More -
News
GAIA BioMedicine Closes JPY 1.3 Billion (USD 11.9 Million) Series B Investment to Advance the GAIA-102 Platform, The Panted “Off-The-Shelf” NK Cells Like Cell Therapy Platform, For Versatile Solid Tumors
More -
News
PMDA received an application for a clinical trial for the IND package of GAIA-102 i.v.
More -
News
New Funding by AMED for a Clinical Trial of GAIA-102 to Treat Malignant Ascites
More